TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Finding Moats in the Diagnostic Lab Industry (Morningstar) Diagnostic Reference Labs: Narrow Moat Firms Have Strong Prospects us.rd.yahoo.com |
Life Technologies Q2 2010 Earnings Call Transcript Life Technologies (LIFE)Q2 2010 Earnings CallJuly 29, 2010 8:30 am ETComplete Story » seekingalpha.com |
Good News for Cell Therapeutics Zacks.com submits: Cell Therapeutics Inc. (CTIC) received a boost when the European Medicines Agency (EMEA) validated the expanded Pediatric Investigation Plan (PIP) filed by the company in July this year for its lead candidate pixantrone. The candidate is being developed for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL) in patients who have not responded to other treatment options. The PIP provides the outline of the process that the company intends to follow to study the drug in children. The validation of the PIP is an important step toward the submission of a Marketing Authorization Application (MAA) and the subsequent approval for pixantrone. Following the validation, the Pediatric Committee (PDCO) of the EMEA will scrutinize the PIP and comment on or approve the content of the plan. The approval of the PIP will enable the company to submit the MAA for its lead candidate in Europe later in the year. The pediatric program intends to evaluate the safety and efficacy of pixantrone compared to chemotherapy drug doxorubicin in children (aged between 6 months and 18 years).Complete Story » seekingalpha.com |
Will Access Pharma Keep Trending Higher? M.E. Garza submits: The stock for Access Pharmaceuticals (ACCP.OB) has been acting very bullishly. During the past two weeks the company's press releases have caught our attention and the stock has been pushing higher. Our advice for investors, just as it was back in September, is to put the stock on their watch lists. While candle stick analysis shows some uncertainty in the market direction at the end of Columbus Day trading, shares of ACCP broke through resistance on Friday and closed up at $2.63+0.13 (5.20%) with the next 2 levels of minor resistance showing at $2.69 and $2.75 respectively. In addition to everything else that is shaping up for them, Greg Zeng of Zacks recently reconfirmed his $8.00 price target for ACCP and stated his belief that "third quarter financials are expected to be better than our estimates."Complete Story » seekingalpha.com |
Medtronic Takes Legal Hit Medtronic reported a sharp drop in quarterly earnings due to lawsuit settlements, as its sales edged higher. online.wsj.com |